Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 219 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (P) Clear all
Completed Phase 4 Interventional Results available

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

NCT00086281
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Xyrem (X), Zolpidem (Z), Modafinil (M), Placebo (P)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Differentiating the Effects of Substance P and Beta-endorphin

NCT01854177
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

NCT01581177
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

NCT06625489
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Part A: Placebo, Nintedanib, GSK3915393
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Cypress, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

NCT01297582
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
ONO-6950
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 5, 2026, 5:16 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Starting a Testosterone and Exercise Program After Hip Injury

NCT02938923
View directory record Official record
Conditions
Hip Fracture, Frailty, Sarcopenia
Interventions
Testosterone, Placebo gel, Supervised exercise training, Home exercise program, Health Education Modules
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Aurora, Colorado • Farmington, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723
View directory record Official record
Conditions
Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions
Placebo Aprepitant, Active Aprepitant
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325
View directory record Official record
Conditions
Hyperuricemia, Gout, Qt Interval, Variation in
Interventions
LC350189 200mg, Placebo, Moxifloxacin 400mg, LC350189 600mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

NCT06945276
View directory record Official record
Conditions
COVID-19
Interventions
ALG-097558, Dabigatran, Itraconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 5, 2026, 5:16 AM EDT
Recruiting Phase 4 Interventional

Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery

NCT05975580
View directory record Official record
Conditions
Obesity
Interventions
Topiramate, Phentermine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 5, 2026, 5:16 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 5, 2026, 5:16 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

NCT01357642
View directory record Official record
Conditions
Asthma
Interventions
epinephrine inhalation aerosol, Placebo
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
33
States / cities
Costa Mesa, California • Los Angeles, California • Mission Viejo, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

NCT00383786
View directory record Official record
Conditions
PTSD
Interventions
NK1 Antagoist (GR205171), Psychophysiology (Trauma Script), Psychophysiology (Verbal Threat), Psychophysiology (Fear Conditioning), Psychophysiology (Affective Modulation), Psychophysiology (Heart rate variability), Lumbar Puncture, 24-hour plasma sampling, MRI
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Reduction of IgE Antibody in Human Allergic Subjects

NCT01280149
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
substance P, substance P injections
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

NCT03824587
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Tenapanor, Placebo, Phosphate Binder Agents
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 5, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

NCT01189396
View directory record Official record
Conditions
Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
A006, Placebo DPI, Proventil-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Medford, Oregon • Portland, Oregon • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 5:16 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectroscopic Imaging at 4T: A Drug Challenge Study

NCT01577706
View directory record Official record
Conditions
AOD Effects and Consequences
Interventions
Alprazolam, Dextroamphetamine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 5, 2026, 5:16 AM EDT